epistaxis
Last edited 07/2022 and last reviewed 09/2022
Epistaxis is one of the commonest presentations at the accident and emergency (A&E) department and is the most common ENT emergency (1). Most cases of nose bleeds are minor or self limiting but rarely can be a life threatening emergency due to massive bleeding (1,2).
An estimated 60 % of the general population has had at least one episode of epistaxis throughout their life time (2).
- out of these only 6% sought medical assistance for it
- 1.6 in 10,000 required hospitalisation (3)
- a bimodal distribution is seen in the poulation
- the incidence peaks at ages less than 10 years and above 50
- in the young, the blood comes from Little's area, a highly vascular area at the anterior border of the nasal septum. With age the site of bleeding moves posteriorly (2)
- rare in children under the age of 2 years and if present is often associated with injury or serious illness (4)
- seasonal variation can also be seen with an increase during the winter months (4)
- occurs frequently in males than in females (2)
Epistaxis may be due to local causes or general causes.
Epistaxis is usually classified into two types:
- anterior bleeding
- posterior bleeding (2)
- epistaxis is common
- an estimated lifetime prevalence in the United States of 60%
- approximately 6% of persons who have nosebleeds seek medical attention.
- management of epistaxis is straightforward in most cases but can be challenging in patients with cardiovascular disease, impaired coagulation, or platelet dysfunction.
- epistaxis is appropriately controlled in a systematic and escalating fashion
- initial management
- patients in the medical setting are advised to apply digital compression to the lower third of the nose for 15 to 20 minutes, which is followed by anterior rhinoscopy
- initial management
- anterior bleeding can usually be controlled with topical vasoconstrictors, tranexamic acid, cautery, or anterior nasal packing
- intranasal tranexamic acid
- study evidence found addition of intranasal tranexamic acid to controlled topical therapy of phenylephrine and lidocaine was linked to a lower rate of need for anterior nasal packing, stay in A+E for >2hrs, and rebleeding in 24hrs (6)
- intranasal tranexamic acid
- continued epistaxis despite these measures requires more aggressive treatment, with the involvement of specialists in otolaryngology and head and neck surgery and, generally, hospital admission
Reference:
- (1) Tikka T. The Aetiology and Management of Epistaxis. Otolaryngology Online Journal (2016) Volume 6, Issue 2
- (2) Kucik CJ. Management of epistaxis. American Family Physician 2005; 71(2)
- (3) Upile T, et al. A change in UK epistaxis management. Eur Arch Otorhinolaryngol. 2008;265(11):1349-54
- (4) McIntosh N, Mok JY, Margerison A. Epidemiology of oronasal hemorrhage in the first 2 years of life: implications for child protection. Pediatrics. 2007;120(5):1074-8
- (5) Seikaly H. Epistaxis. N Engl J Med 2021; 384:944-951
- (6) Hosseinialhashemi M et al. Intranasal Topical Application of Tranexamic Acid in Atraumatic Anterior Epistaxis: A Double-Blind Randomized Clinical Trial. Ann Emerg Med. 2022 Jun 22:S0196-0644(22)00247-5.
blood supply to the nose and sinuses